|
US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
|
EP0781331B1
(en)
|
1994-08-20 |
2008-09-03 |
Gendaq Limited |
Improvements in or relating to binding proteins for recognition of dna
|
|
GB9824544D0
(en)
*
|
1998-11-09 |
1999-01-06 |
Medical Res Council |
Screening system
|
|
US7262055B2
(en)
|
1998-08-25 |
2007-08-28 |
Gendaq Limited |
Regulated gene expression in plants
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6410248B1
(en)
|
1998-01-30 |
2002-06-25 |
Massachusetts Institute Of Technology |
General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
|
|
ES2341926T3
(en)
|
1998-03-02 |
2010-06-29 |
Massachusetts Institute Of Technology |
POLYPROTEINS WITH ZINC FINGERS THAT HAVE IMPROVED LINKERS.
|
|
WO1999047656A2
(en)
*
|
1998-03-17 |
1999-09-23 |
Gendaq Limited |
Nucleic acid binding proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7943731B1
(en)
|
1999-08-11 |
2011-05-17 |
Massachusetts Institute Of Technology |
Dimerizing peptides
|
|
CA2394850C
(en)
|
1999-12-06 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
|
DE60126913T2
(en)
|
2000-01-24 |
2007-06-28 |
Gendaq Ltd. |
NUCLEIC ACID BINDING POLYPEPTIDE IS IDENTIFIED BY FLEXIBLE LINKER-LINKED NUCLEIC ACID ACID
|
|
AU5587001A
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences Inc |
Databases of regulatory sequences; methods of making and using same
|
|
US6511808B2
(en)
|
2000-04-28 |
2003-01-28 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
|
US7923542B2
(en)
|
2000-04-28 |
2011-04-12 |
Sangamo Biosciences, Inc. |
Libraries of regulatory sequences, methods of making and using same
|
|
AU2001257421A1
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences, Inc. |
Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
|
|
AU2001252428A1
(en)
*
|
2000-05-08 |
2001-11-20 |
Gendaq Limited |
Nucleic acid binding polypeptides
|
|
IL154059A0
(en)
*
|
2000-07-21 |
2003-07-31 |
Syngenta Participations Ag |
Zinc finger domain recognition code and uses thereof
|
|
AU2001285252A1
(en)
*
|
2000-08-25 |
2002-03-13 |
Gendaq, Ltd. |
Analysis of binding interactions
|
|
US6905816B2
(en)
|
2000-11-27 |
2005-06-14 |
Intelligent Medical Devices, Inc. |
Clinically intelligent diagnostic devices and methods
|
|
US7067317B2
(en)
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
|
CA2431308C
(en)
|
2000-12-07 |
2010-04-13 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
|
US7947469B2
(en)
|
2001-01-22 |
2011-05-24 |
Gendaq, Ltd. |
Modulation of HIV infection
|
|
AU2002241946B2
(en)
|
2001-01-22 |
2007-04-26 |
Sangamo Therapeutics, Inc. |
Modified zinc finger binding proteins
|
|
EP2266396A3
(en)
|
2001-09-24 |
2011-06-15 |
Sangamo BioSciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
|
US7262054B2
(en)
|
2002-01-22 |
2007-08-28 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
|
US8106255B2
(en)
|
2002-01-23 |
2012-01-31 |
Dana Carroll |
Targeted chromosomal mutagenasis using zinc finger nucleases
|
|
WO2003064665A2
(en)
|
2002-02-01 |
2003-08-07 |
Oxford Biomedica (Uk) Limited |
Viral vector
|
|
AU2003250115B2
(en)
|
2002-07-26 |
2009-03-12 |
Basf Plant Science Gmbh |
Inversion of the negative-selective effect of negative marker proteins using selection methods
|
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
|
JP2006502748A
(en)
|
2002-09-05 |
2006-01-26 |
カリフォルニア インスティテュート オブ テクノロジー |
Methods of using chimeric nucleases to induce gene targeting
|
|
GB0228289D0
(en)
|
2002-12-04 |
2003-01-08 |
Genome Inst Of Singapore Nat U |
Method
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
DK2927318T3
(en)
|
2003-08-08 |
2020-08-03 |
Sangamo Therapeutics Inc |
Method and compositions for targeted cleavage and recombination
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
EP1678315B1
(en)
|
2003-09-19 |
2011-08-03 |
Sangamo BioSciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
EP1732945B1
(en)
|
2004-04-08 |
2014-12-24 |
Sangamo BioSciences, Inc. |
Methods and compositions for modulating cardiac contractility
|
|
US20050282193A1
(en)
|
2004-04-23 |
2005-12-22 |
Bulyk Martha L |
Space efficient polymer sets
|
|
KR20070060115A
(en)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
Compositions and Methods for Protein Production
|
|
JP4988606B2
(en)
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Anti-angiogenic methods and compositions
|
|
WO2007014275A2
(en)
|
2005-07-26 |
2007-02-01 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
CA2651494C
(en)
|
2006-05-25 |
2015-09-29 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
|
CA2651499C
(en)
|
2006-05-25 |
2015-06-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for ccr-5 gene inactivation
|
|
CA2660485C
(en)
|
2006-08-11 |
2016-04-12 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease-mediated homologous recombination
|
|
CA2667414C
(en)
*
|
2006-11-13 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the human glucocorticoid receptor locus
|
|
ES2586210T3
(en)
|
2006-12-14 |
2016-10-13 |
Sangamo Biosciences, Inc. |
Optimized non-canon zinc finger proteins
|
|
AU2008244473B2
(en)
|
2007-04-26 |
2013-06-20 |
Sangamo Therapeutics, Inc. |
Targeted integration into the PPP1R12C locus
|
|
EP2171052B1
(en)
|
2007-07-12 |
2014-08-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US9506120B2
(en)
|
2007-09-27 |
2016-11-29 |
Sangamo Biosciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
SI2205749T1
(en)
|
2007-09-27 |
2016-09-30 |
Dow Agrosciences, Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
US8936936B2
(en)
|
2007-10-25 |
2015-01-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
JP2011518555A
(en)
|
2008-04-14 |
2011-06-30 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Linear donor constructs for targeted integration
|
|
DK2268129T3
(en)
|
2008-04-21 |
2015-09-28 |
Danziger Innovations Ltd |
PLANTEVIRUSEKSPRESSIONSVEKTORER AND USE THEREOF FOR GENERATING GENOTYPEVARIATIONER into plant genomes
|
|
CN102027118B
(en)
|
2008-04-30 |
2014-07-30 |
桑比欧公司 |
Neural regenerating cells with alterations in DNA methylation
|
|
AU2009260888B2
(en)
|
2008-05-28 |
2014-09-11 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
EP2294191B1
(en)
|
2008-06-10 |
2016-09-28 |
Sangamo BioSciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
US8703489B2
(en)
|
2008-08-22 |
2014-04-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
EP2344660B1
(en)
|
2008-10-29 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
CN102625655B
(en)
|
2008-12-04 |
2016-07-06 |
桑格摩生物科学股份有限公司 |
Zinc finger nuclease is used to carry out genome editor in rats
|
|
CA2747124C
(en)
|
2008-12-17 |
2018-09-04 |
Dow Agrosciences Llc |
Targeted integration into the zp15 locus
|
|
JP5827132B2
(en)
|
2009-02-04 |
2015-12-02 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for treating neuropathy
|
|
US8871905B2
(en)
|
2009-03-20 |
2014-10-28 |
Sangamo Biosciences, Inc. |
Modification of CXCR4 using engineered zinc finger proteins
|
|
EP2419511B1
(en)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
AU2010266705B2
(en)
|
2009-06-30 |
2014-06-05 |
Sangamo Therapeutics, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
JP5866283B2
(en)
|
2009-07-28 |
2016-02-17 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Methods and compositions for treating trinucleotide repeat disease
|
|
EP2462230B1
(en)
|
2009-08-03 |
2015-07-15 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
|
NZ619886A
(en)
|
2009-08-11 |
2015-03-27 |
Sangamo Biosciences Inc |
Organisms homozygous for targeted modification
|
|
WO2011048600A1
(en)
|
2009-10-21 |
2011-04-28 |
Danziger Innovations Ltd. |
Generating genotypic variations in plant genomes by gamete infection
|
|
RU2568056C2
(en)
|
2009-10-22 |
2015-11-10 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Constructed proteins with zinc fingers directed towards genes of plants involved in biosynthesis of fatty acids
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2504439B1
(en)
|
2009-11-27 |
2016-03-02 |
BASF Plant Science Company GmbH |
Optimized endonucleases and uses thereof
|
|
PH12012501491B1
(en)
|
2010-01-22 |
2019-06-28 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
|
CA2788560A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
|
CA2788850C
(en)
|
2010-02-09 |
2019-06-25 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
SG185367A1
(en)
|
2010-04-26 |
2012-12-28 |
Sangamo Biosciences Inc |
Genome editing of a rosa locus using zinc-finger nucleases
|
|
HRP20200254T1
(en)
|
2010-05-03 |
2020-05-29 |
Sangamo Therapeutics, Inc. |
PREPARATIONS FOR CONNECTING ZINC FINGER MODULE
|
|
EP2571512B1
(en)
|
2010-05-17 |
2017-08-23 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
EP2596011B1
(en)
|
2010-07-21 |
2018-10-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a hla locus
|
|
EP2622090B1
(en)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
WO2012051343A1
(en)
|
2010-10-12 |
2012-04-19 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia b
|
|
US9267123B2
(en)
|
2011-01-05 |
2016-02-23 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
WO2012139045A1
(en)
|
2011-04-08 |
2012-10-11 |
Gilead Biologics, Inc. |
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
IL277027B
(en)
|
2011-09-21 |
2022-07-01 |
Sangamo Therapeutics Inc |
Methods and preparations for regulating transgene expression
|
|
US8895264B2
(en)
|
2011-10-27 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
US9458205B2
(en)
|
2011-11-16 |
2016-10-04 |
Sangamo Biosciences, Inc. |
Modified DNA-binding proteins and uses thereof
|
|
EP2806881A1
(en)
|
2012-01-27 |
2014-12-03 |
SanBio, Inc. |
Methods and compositions for modulating angiogenesis and vasculogenesis
|
|
RU2639277C2
(en)
|
2012-02-29 |
2017-12-20 |
Сангамо Байосайенсиз, Инк. |
Methods and compositions for huntington disease treatment
|
|
DK2839013T3
(en)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
NON-DISRUPTIVE-GEN-TARGETING
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
MX369788B
(en)
|
2012-05-02 |
2019-11-21 |
Dow Agrosciences Llc |
Targeted modification of malate dehydrogenase.
|
|
EP2847338B1
(en)
|
2012-05-07 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
WO2013169398A2
(en)
|
2012-05-09 |
2013-11-14 |
Georgia Tech Research Corporation |
Systems and methods for improving nuclease specificity and activity
|
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
DK2872625T3
(en)
|
2012-07-11 |
2017-02-06 |
Sangamo Biosciences Inc |
METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISEASES
|
|
CA2882499C
(en)
|
2012-08-29 |
2023-09-26 |
Sangamo Biosciences, Inc. |
Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
|
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
EP2893006B1
(en)
|
2012-09-07 |
2018-08-22 |
Dow AgroSciences LLC |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
AR093980A1
(en)
|
2012-12-13 |
2015-07-01 |
Dow Agrosciences Llc |
PRECISION GENES THAT HAVE A PARTICULAR LOCUS IN THE CORN AS THE OBJECTIVE
|
|
JP6491113B2
(en)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
KR102223568B1
(en)
|
2013-04-05 |
2021-03-04 |
다우 아그로사이언시즈 엘엘씨 |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
WO2015031619A1
(en)
|
2013-08-28 |
2015-03-05 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN116836957A
(en)
|
2013-10-17 |
2023-10-03 |
桑格摩生物科学股份有限公司 |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3066110B1
(en)
|
2013-11-04 |
2021-12-29 |
Corteva Agriscience LLC |
Optimal maize loci
|
|
JP6634022B2
(en)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
Optimal soybean loci
|
|
BR102014027466B1
(en)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
RECOMBINANT NUCLEIC ACID MOLECULE, METHOD FOR PRODUCING A TRANSGENIC PLANT CELL AND USES OF A SOYBEAN PLANT, PART OF A SOYBEAN PLANT, OR A TRANSGENIC SOYBEAN PLANT CELL
|
|
AU2014341929B2
(en)
|
2013-11-04 |
2017-11-30 |
Corteva Agriscience Llc |
Optimal maize loci
|
|
KR102431079B1
(en)
|
2013-11-11 |
2022-08-11 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for treating huntington's disease
|
|
EP3960856A1
(en)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
AU2014363991B2
(en)
|
2013-12-09 |
2020-08-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
|
DK3102673T3
(en)
|
2014-02-03 |
2020-07-06 |
Sangamo Therapeutics Inc |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-TALASSEMI
|
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
WO2015143177A1
(en)
|
2014-03-21 |
2015-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
|
WO2015153889A2
(en)
|
2014-04-02 |
2015-10-08 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
WO2015172153A1
(en)
|
2014-05-09 |
2015-11-12 |
Yale University |
Topical formulation of hyperbranched polyglycerol-coated particles thereof
|
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
|
CA2947622A1
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Genome editing methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
CA2954201A1
(en)
|
2014-07-08 |
2016-01-14 |
Vib Vzw |
Means and methods to increase plant yield
|
|
BR112017000925B1
(en)
|
2014-07-14 |
2023-10-10 |
Washington State University |
METHOD OF REPRODUCTION OF PIGS, METHOD OF GENERATING A PIG WITHOUT ANY FUNCTIONAL SPERMATOGONE CELLS, METHOD OF PRODUCING A RECEIVING MALE AND METHOD OF PRODUCING PIGS
|
|
CA2954414A1
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
US11278572B2
(en)
|
2014-07-18 |
2022-03-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
HUE055583T2
(en)
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
HK1246690A1
(en)
|
2015-01-21 |
2018-09-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
JP6800859B2
(en)
|
2015-01-26 |
2020-12-16 |
フェイト セラピューティクス，インコーポレイテッド |
Methods and Compositions for Inducing Hematopoietic Cell Differentiation
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3277823B1
(en)
|
2015-04-03 |
2023-09-13 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
WO2016168229A1
(en)
|
2015-04-15 |
2016-10-20 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
RU2017137599A
(en)
|
2015-04-15 |
2019-05-15 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
VEGETABLE PROMOTER FOR THE TRANSGEN EXPRESSION
|
|
US11845928B2
(en)
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
CA2984013A1
(en)
|
2015-05-12 |
2016-11-17 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CN108024544B
(en)
|
2015-07-13 |
2022-04-29 |
桑格摩生物治疗股份有限公司 |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
|
SI3331355T1
(en)
|
2015-08-06 |
2024-10-30 |
The Curators Of The University Of Missouri |
Porcine reproductive and respiratory syndrome virus (prrsv)-resistant porcine and cells having modified cd163 genes
|
|
TW201718861A
(en)
|
2015-09-22 |
2017-06-01 |
道禮責任有限公司 |
Plant promoter and 3'UTR for transgene expression
|
|
TW201718862A
(en)
|
2015-09-22 |
2017-06-01 |
Dow Agrosciences Llc |
Plant promoter and 3' UTR for transgene expression
|
|
JP6853257B2
(en)
|
2015-09-23 |
2021-03-31 |
サンガモ セラピューティクス， インコーポレイテッド |
HTT repressor and its use
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
US10280429B2
(en)
|
2015-10-22 |
2019-05-07 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
WO2017078935A1
(en)
|
2015-11-04 |
2017-05-11 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
KR20250033315A
(en)
|
2015-11-04 |
2025-03-07 |
페이트 세러퓨틱스, 인코포레이티드 |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
AU2016349504B2
(en)
|
2015-11-04 |
2023-02-09 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
EA201891317A3
(en)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
THERAPEUTIC TARGETS FOR CORRECTION OF HUMAN DISTROPHIN GENE BY EDITING GENES AND METHODS OF THEIR APPLICATION
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
IL259935B2
(en)
|
2015-12-18 |
2023-03-01 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
KR20180101442A
(en)
|
2016-02-02 |
2018-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
Compositions for linking DNA-binding domains and cleavage domains
|
|
EP3416976A2
(en)
|
2016-02-16 |
2018-12-26 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
|
AU2017221424A1
(en)
|
2016-02-16 |
2018-09-20 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
|
WO2017165655A1
(en)
|
2016-03-23 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
|
WO2017189870A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
|
CA3028002A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
JP7033583B2
(en)
|
2016-07-13 |
2022-03-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Methods, compositions and kits for increasing genome editing efficiency
|
|
JP7490211B2
(en)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Therapeutic Applications of CPF1-Based Genome Editing
|
|
CN114652735A
(en)
|
2016-07-27 |
2022-06-24 |
凯斯西储大学 |
Compounds and methods for promoting myelination
|
|
JP7066126B2
(en)
|
2016-08-09 |
2022-05-13 |
ブイアイビー ブイゼットダブリュ |
Cellulose synthase inhibitors and mutant plants
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
LT3504229T
(en)
|
2016-08-24 |
2021-12-10 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
JP7256739B2
(en)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス， インコーポレイテッド |
Modulation of liver genes
|
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
US10519459B2
(en)
|
2016-10-03 |
2019-12-31 |
Dow Agrosciences Llc |
Plant promoter from Panicum virgatum
|
|
US10400246B2
(en)
|
2016-10-03 |
2019-09-03 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
IL266047B2
(en)
|
2016-10-20 |
2025-02-01 |
Sangamo Therapeutics Inc |
Methods and preparations for the treatment of Fabry disease
|
|
WO2018081138A1
(en)
|
2016-10-24 |
2018-05-03 |
Yale University |
Biodegradable contraceptive implants
|
|
JP7108608B2
(en)
|
2016-10-31 |
2022-07-28 |
サンガモ セラピューティクス， インコーポレイテッド |
Genetic modification of SCID-associated genes in hematopoietic stem and progenitor cells
|
|
IL266862B2
(en)
|
2016-12-01 |
2024-01-01 |
Sangamo Therapeutics Inc |
Tau modulators and methods and compositions for delivery thereof
|
|
AU2017367695A1
(en)
|
2016-12-02 |
2019-06-13 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
JP7416406B2
(en)
|
2016-12-08 |
2024-01-17 |
ケース ウェスタン リザーブ ユニバーシティ |
Methods and compositions for increasing functional myelin production
|
|
US20200085758A1
(en)
|
2016-12-16 |
2020-03-19 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
|
AU2018224387B2
(en)
|
2017-02-22 |
2024-08-08 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
|
WO2018195418A1
(en)
|
2017-04-20 |
2018-10-25 |
Oregon Health & Science University |
Human gene correction
|
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
US10457955B2
(en)
|
2017-06-28 |
2019-10-29 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
EP3665271A4
(en)
|
2017-08-08 |
2021-04-28 |
Sangamo Therapeutics, Inc. |
CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
|
|
EP3692063A1
(en)
|
2017-10-03 |
2020-08-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
JP2021502085A
(en)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
Genetic modification of cytokine-induced SH2-containing protein (CISH) gene
|
|
WO2019094928A1
(en)
|
2017-11-10 |
2019-05-16 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
|
WO2019100053A1
(en)
|
2017-11-20 |
2019-05-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2α to improve muscle generation and repair
|
|
EP3717505A4
(en)
|
2017-12-01 |
2021-12-01 |
Encoded Therapeutics, Inc. |
MODIFIED DNA BINDING PROTEINS
|
|
US11459577B2
(en)
|
2017-12-18 |
2022-10-04 |
Syngenta Participations Ag |
Targeted insertion sites in the maize genome
|
|
EP4083192A1
(en)
|
2017-12-22 |
2022-11-02 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
ES2980444T3
(en)
|
2018-01-17 |
2024-10-01 |
Vertex Pharma |
DNA-PK inhibitors
|
|
US12121524B2
(en)
|
2018-01-17 |
2024-10-22 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
KR20200110687A
(en)
|
2018-01-17 |
2020-09-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Quinoxalinone compounds, compositions, methods and kits for increasing genome editing efficiency
|
|
EP3740580A4
(en)
|
2018-01-19 |
2021-10-20 |
Duke University |
GENOMIC ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
|
|
WO2019157324A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
JP7575271B2
(en)
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
Engineered immune effector cells and uses thereof
|
|
EP3775237A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
MX2020010460A
(en)
|
2018-04-05 |
2021-01-29 |
Juno Therapeutics Inc |
T-CELL RECEPTORS, AND ENGINEERED CELLS EXPRESSING THEM.
|
|
BR112020020245A2
(en)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
CN112105420A
(en)
|
2018-05-11 |
2020-12-18 |
克里斯珀医疗股份公司 |
Methods and compositions for treating cancer
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
GB201809273D0
(en)
|
2018-06-06 |
2018-07-25 |
Vib Vzw |
Novel mutant plant cinnamoyl-coa reductase proteins
|
|
EP3802839A1
(en)
|
2018-06-07 |
2021-04-14 |
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) |
Nucleic acid constructs and methods of using same
|
|
US20210337753A1
(en)
|
2018-06-07 |
2021-11-04 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization |
Methods of regenerating and transforming cannabis
|
|
US11939593B2
(en)
|
2018-08-01 |
2024-03-26 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
|
CA3109592A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
CA3111186A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
|
BR112021003818A2
(en)
|
2018-08-31 |
2021-05-25 |
Yale University |
composition, pharmaceutical composition and method for modifying the genome of a cell
|
|
AU2019344927A1
(en)
|
2018-09-18 |
2021-04-01 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (PD1) specific nucleases
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
KR20210070344A
(en)
|
2018-10-02 |
2021-06-14 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for modulation of tau protein
|
|
WO2020095107A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
JP7471289B2
(en)
|
2018-11-07 |
2024-04-19 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Anti-LIV1 immune cell cancer therapy
|
|
KR20210092236A
(en)
|
2018-11-07 |
2021-07-23 |
크리스퍼 테라퓨틱스 아게 |
Anti-PTK7 immune cell cancer therapy
|
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
|
SG11202105480WA
(en)
|
2018-12-02 |
2021-06-29 |
Fate Therapeutics Inc |
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
AU2019391114B2
(en)
|
2018-12-05 |
2026-01-29 |
Vertex Pharmaceuticals Incorporated |
Gene-editing systems for editing a cystic fibrosis transmembrane regulator (CFTR) gene
|
|
GB201820109D0
(en)
|
2018-12-11 |
2019-01-23 |
Vib Vzw |
Plants with a lignin trait and udp-glycosyltransferase mutation
|
|
CN113474328B
(en)
|
2019-01-11 |
2025-07-11 |
爱康泰生治疗公司 |
Lipids for lipid nanoparticle delivery of active agents
|
|
US12156877B1
(en)
|
2019-01-15 |
2024-12-03 |
The Regents Of The University Of California |
Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
|
|
WO2020154595A1
(en)
|
2019-01-24 |
2020-07-30 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
WO2020185628A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Cd40l compositions and methods for tunable regulation
|
|
CA3132167A1
(en)
|
2019-04-02 |
2020-10-08 |
Weston P. MILLER IV |
Methods for the treatment of beta-thalassemia
|
|
US12139517B2
(en)
|
2019-04-23 |
2024-11-12 |
Sangamo Therapeutics, Inc. |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
|
BR112021021200A2
(en)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides, and methods
|
|
US20220184131A1
(en)
|
2019-05-01 |
2022-06-16 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
KR102808368B1
(en)
|
2019-05-29 |
2025-05-15 |
엔코디드 테라퓨틱스, 인크. |
Compositions and methods for selective gene regulation
|
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
|
MA56388A
(en)
|
2019-06-27 |
2022-05-04 |
Crispr Therapeutics Ag |
USE OF CHEMERA ANTIGEN RECEPTOR T LYMPHOCYTES AND NK CELL INHIBITORS FOR THE TREATMENT OF CANCER
|
|
AU2020314969A1
(en)
|
2019-07-17 |
2022-02-03 |
Fate Therapeutics, Inc. |
Immune effector cell engineering and use thereof
|
|
JP2022543112A
(en)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー，インコーポレイテッド |
DUX4-expressing cells and their uses
|
|
US20230025289A1
(en)
|
2019-08-23 |
2023-01-26 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
|
CN115151275A
(en)
|
2019-08-30 |
2022-10-04 |
耶鲁大学 |
Compositions and methods for delivering nucleic acids to cells
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
AU2020356962A1
(en)
|
2019-10-02 |
2022-04-14 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
WO2021067864A1
(en)
|
2019-10-02 |
2021-04-08 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for treatment of prion disease
|
|
TW202132565A
(en)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin recombinase variants
|
|
CN115279419A
(en)
|
2019-11-01 |
2022-11-01 |
美商圣加莫治疗股份有限公司 |
Compositions and methods for genome engineering
|
|
US20230056856A1
(en)
|
2020-01-08 |
2023-02-23 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
MX2022008953A
(en)
|
2020-01-22 |
2022-08-15 |
Sangamo Therapeutics Inc |
Zinc finger protein transcription factors for repressing tau expression.
|
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
|
KR20220158046A
(en)
|
2020-03-25 |
2022-11-29 |
사나 바이오테크놀로지, 인크. |
Immunocompromised Neuronal Cells for Treatment of Nervous System Disorders and Conditions
|
|
US20230212613A1
(en)
|
2020-05-06 |
2023-07-06 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
AU2021269103A1
(en)
|
2020-05-06 |
2022-12-15 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
CN115835873A
(en)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
Method for producing donor batch cells expressing recombinant receptors
|
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
MX2022015863A
(en)
|
2020-06-19 |
2023-03-23 |
Fate Therapeutics Inc |
Combining ipsc-derived effector cell types for immunotherapy use.
|
|
CN116234558A
(en)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
Engineered T cells, related polynucleotides and methods for conditionally expressing recombinant receptors
|
|
EP4182297B1
(en)
|
2020-07-16 |
2025-09-03 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
MX2023001831A
(en)
|
2020-08-13 |
2023-06-29 |
Sana Biotechnology Inc |
METHODS OF TREATMENT OF SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS AND ASSOCIATED METHODS AND COMPOSITIONS.
|
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
EP4204002A1
(en)
|
2020-08-31 |
2023-07-05 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
IL301012A
(en)
|
2020-09-23 |
2023-05-01 |
Crispr Therapeutics Ag |
Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
|
|
WO2022067122A1
(en)
|
2020-09-25 |
2022-03-31 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
IL301795A
(en)
|
2020-10-02 |
2023-05-01 |
Sangamo Therapeutics Inc |
Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022101641A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
MX2023006395A
(en)
|
2020-12-03 |
2023-06-15 |
Century Therapeutics Inc |
GENETICALLY DESIGNED CELLS AND USES OF THESE.
|
|
WO2022137181A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
|
MX2023006207A
(en)
|
2020-12-31 |
2023-08-09 |
Sana Biotechnology Inc |
Methods and compositions for modulating car-t activity.
|
|
US20240318159A1
(en)
|
2021-01-12 |
2024-09-26 |
Mitolab Inc. |
Context-dependent, double-stranded dna-specific deaminases and uses thereof
|
|
EP4305153A1
(en)
|
2021-03-09 |
2024-01-17 |
CRISPR Therapeutics AG |
Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
|
|
US20250354978A1
(en)
|
2021-03-22 |
2025-11-20 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
EP4319799A1
(en)
|
2021-04-07 |
2024-02-14 |
Century Therapeutics, Inc. |
Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
|
|
MX2023011927A
(en)
|
2021-04-07 |
2023-10-23 |
Century Therapeutics Inc |
COMPOSITIONS AND METHODS FOR THE GENERATION OF GAMMA-DELTA T LYMPHOCYTES FROM INDUCED PLURIPOTENT STEM CELLS.
|
|
AU2022255166A1
(en)
|
2021-04-07 |
2023-09-28 |
Century Therapeutics, Inc. |
Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
|
|
CN117460820A
(en)
|
2021-05-05 |
2024-01-26 |
富士胶片细胞动力公司 |
Methods and compositions regarding iPSC-derived microglia
|
|
CN117881777A
(en)
|
2021-05-26 |
2024-04-12 |
富士胶片细胞动力公司 |
Method to prevent rapid gene silencing in pluripotent stem cells
|
|
JP2024521619A
(en)
|
2021-05-27 |
2024-06-04 |
サナ バイオテクノロジー，インコーポレイテッド |
Hypoimmunogenic cells containing engineered HLA-E or HLA-G
|
|
US20240316198A1
(en)
|
2021-07-14 |
2024-09-26 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
EP4377460A1
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4384189A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
JP2024534772A
(en)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
Genetically modified cells for allogeneic cell therapy
|
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
TW202321435A
(en)
|
2021-08-11 |
2023-06-01 |
美商薩那生物科技公司 |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
AU2022344320A1
(en)
|
2021-09-10 |
2024-03-07 |
FUJIFILM Cellular Dynamics, Inc. |
Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
|
|
WO2023042079A1
(en)
|
2021-09-14 |
2023-03-23 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
|
EP4419676A1
(en)
|
2021-10-21 |
2024-08-28 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
|
EP4419117A1
(en)
|
2021-10-22 |
2024-08-28 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
CN118339279A
(en)
|
2021-10-29 |
2024-07-12 |
富士胶片细胞动力公司 |
Dopaminergic neurons comprising mutations and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4452304A1
(en)
|
2021-12-22 |
2024-10-30 |
CRISPR Therapeutics AG |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
|
WO2023122722A1
(en)
|
2021-12-22 |
2023-06-29 |
Sangamo Therapeutics, Inc. |
Novel zinc finger fusion proteins for nucleobase editing
|
|
MX2024007528A
(en)
|
2021-12-23 |
2024-08-30 |
Sana Biotechnology Inc |
CHIMERIC ANTIGEN RECEPTOR (CAR) T LYMPHOCYTES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ASSOCIATED METHODS.
|
|
AU2022423987A1
(en)
|
2021-12-29 |
2024-07-11 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
|
|
EP4460571A1
(en)
|
2022-01-05 |
2024-11-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
CA3247928A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
TW202340457A
(en)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
Allogeneic therapeutic cells
|
|
EP4486890A1
(en)
|
2022-03-01 |
2025-01-08 |
CRISPR Therapeutics AG |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023180904A1
(en)
|
2022-03-21 |
2023-09-28 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
|
TW202400778A
(en)
|
2022-03-23 |
2024-01-01 |
瑞士商Ｃｒｉｓｐｒ治療公司 |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
|
JP7707304B2
(en)
|
2022-04-08 |
2025-07-14 |
フェイト セラピューティクス，インコーポレイティド |
Chimeric antigen receptors for tumor targeting
|
|
JP7701453B2
(en)
|
2022-04-08 |
2025-07-01 |
フェイト セラピューティクス，インコーポレイティド |
Solid tumor targeting scaffold bearing cells and uses thereof
|
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
|
CN119630695A
(en)
|
2022-06-08 |
2025-03-14 |
世纪治疗股份有限公司 |
Genetically engineered cells expressing CD16 variants and NKG2D and uses thereof
|
|
US20250090582A1
(en)
|
2022-06-08 |
2025-03-20 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
|
|
WO2023240169A1
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
|
|
AU2023290692A1
(en)
|
2022-06-17 |
2025-01-23 |
Crispr Therapeutics Ag |
LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
|
|
WO2023248145A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Compositions and methods for treating human immunodeficiency virus
|
|
US20250381304A1
(en)
|
2022-06-21 |
2025-12-18 |
Crispr Therapeutics Ag |
Methods and compositions for in vivo editing of stem cells
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
WO2024003786A1
(en)
|
2022-06-29 |
2024-01-04 |
Crispr Therapeutics Ag |
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
|
|
KR20250038661A
(en)
|
2022-06-29 |
2025-03-19 |
후지필름 홀딩스 아메리카 코포레이션 |
IPSC-derived stellate cells and methods of using them
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
JP2025523965A
(en)
|
2022-07-22 |
2025-07-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Dendrimer-enabled targeted intracellular CRISPR/CAS system delivery and gene editing
|
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
|
AU2023325407A1
(en)
|
2022-08-19 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
JP2025531268A
(en)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Compositions, systems, and methods for modulating T cell function
|
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|
|
CN120897933A
(en)
|
2022-10-11 |
2025-11-04 |
耶鲁大学 |
Compositions and methods using cell-penetrating antibodies
|
|
WO2024102838A1
(en)
|
2022-11-09 |
2024-05-16 |
Century Therapeutics, Inc. |
Engineered interleukin-7 receptors and uses thereof
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
IL320650A
(en)
|
2022-11-10 |
2025-07-01 |
Century Therapeutics Inc |
Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
|
|
WO2024119101A1
(en)
|
2022-12-01 |
2024-06-06 |
Yale University |
Stimuli-responsive traceless engineering platform for intracellular payload delivery
|
|
WO2024137677A1
(en)
|
2022-12-19 |
2024-06-27 |
FUJIFILM Holdings America Corporation |
Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
|
|
JP2026500040A
(en)
|
2022-12-23 |
2026-01-05 |
エピジェニック セラピューティクス プライベート リミテッド |
Conjugates and their uses
|
|
TW202440931A
(en)
|
2022-12-23 |
2024-10-16 |
大陸商益杰立科（上海）生物科技有限公司 |
Fusions and uses thereof
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024173645A1
(en)
|
2023-02-15 |
2024-08-22 |
Arbor Biotechnologies, Inc. |
Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
|
|
WO2024192108A1
(en)
|
2023-03-14 |
2024-09-19 |
Evolveimmune Therapeutics, Inc. |
Genetically modified car t cells and methods of making and using the same
|
|
US20240366670A1
(en)
|
2023-04-21 |
2024-11-07 |
Kite Pharma, Inc. |
Allogenic therapeutic cells with reduced risk of immune rejection
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
AU2024301706A1
(en)
|
2023-07-21 |
2026-02-05 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025101938A2
(en)
|
2023-11-10 |
2025-05-15 |
Century Therapeutics, Inc. |
Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
|
|
WO2025106626A1
(en)
|
2023-11-15 |
2025-05-22 |
Century Therapeutics, Inc. |
Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025207798A1
(en)
|
2024-03-26 |
2025-10-02 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
|
|
WO2025207795A1
(en)
|
2024-03-26 |
2025-10-02 |
Juno Therapeutics, Inc. |
Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
|
|
WO2025224715A1
(en)
|
2024-04-26 |
2025-10-30 |
King Abdullah Univeristy Of Science And Technology |
Methods for improving precise genome modification and reducing unwanted mutations by crispr-cas editing
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2026006832A1
(en)
|
2024-06-28 |
2026-01-02 |
University Of Connecticut |
Gene modulation for treating cancer
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|